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An increasing number of manuscript on
neurological topics have been submitted and
published during year 2008, ranging from
head injury, subarachnoid hemorrhage,
electrical disturbances and delirium.
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Traumatic brain injury
Recent experimental evidence suggests that matrix
metalloproteinases (MMPs) are implicated in the patho-
physiology of traumatic brain injury (TBI) by increasing
blood–brain barrier permeability and exacerbating post-
traumatic edema. MMPs are zinc-dependent and cell
surface-associated endopeptidases that cleave all extra-
cellular matrix (ECM) components, including collagen,
laminin, and proteoglycans. The MMPs and their potential
deleterious effects are tightly regulated at transcriptional
and post-transcriptional levels through proform activation
and by MMP tissue inhibitors (TIMPs) Two members of
this family have a very specific and marked activity
against gelatin and are termed gelatinases. In vitro studies
have demonstrated that the secretion of gelatinases is
significantly increased in cortical cultures when mechan-
ical injury is simulated. In human TBI, data about the
presence of gelatinases in the brain extracellular fluid
(ECF) and their temporal profile, both in plasma and ECF,
are still lacking. Sahuquillo’s group [1] examined the
acute profile of MMP-2 and MMP-9 in the plasma of
patients with moderate or severe TBI and, more interest-
ingly, in the brain extracellular fluid (ECF). High levels of
gelatinases were found in plasma and brain ECF in the
early phase of TBI, indicating that both local and systemic
trauma-induced upregulation of gelatinases in the acute
phase might play an important role in the pathophysiology
of TBI and could be a future therapeutic target.
After admission in intensive care units (ICU), clini-
cians are often challenged with the contemporary
management of intracranial priorities and extra-cranial
complications. The incidence and severity of non-neu-
rological organ dysfunction in acute neurological
patients has been studied analyzing the database from
the observational Sepsis Occurrence in Acutely Ill
Patients (SOAP) study in 198 ICU [2]. The data comes
from 373 cases, 12% of the 3,147 patients in the SOAP
database, admitted with a neurological diagnosis, 41%
with traumatic brain injury and 50% with cerebrovas-
cular accident.
Neurological patients developed ICU-acquired sepsis
and respiratory failure more frequently than the other
patients, and length of stay, ICU and hospital mortality
were higher compared with non-neurological patients.
Multivariate logistic analysis showed that cardiovascular
failure, hepatic failure, and ALI/ARDS were factors
independently associated with a higher risk of death in the
ICU.
One of the main intracranial therapy targets in the
acute phase is high intracranial pressure (HICP). Mauritz
[3] described ICP use in a sample of 1,856 severe TBI
from a registry of patients admitted to Austrian ICUs
between 1998 and 2004. Mauritz aimed to investigate
reasons why patients did or did not receive ICP
monitoring and to describe factors influencing hospital
mortality after severe TBI. The ad hoc created statistical
model explains only 37% of the variance of the use of ICP
monitoring, but clearly showed that severity and age are
importantly associated with ICP monitoring. The more
severe, as the less injured, cases were less likely to be
submitted to ICP. That is likely to reflect a clinical
judgment concerning who can benefit from invasive
monitoring. An evaluation of potential salvageability is
part of the decisional analysis. Interestingly, no clear,
standardized definition of ‘‘salvageability’’ is available.
Older patients are less often monitored. The second aim
of the paper was to analyze the impact of several pre-
dictors, including ICP monitoring, on mortality at hospital
discharge. The study confirms a clear association between
the number of cases treated by center per year and better
outcome. This supports the benefit of centralization, as
shown in TBI and other neurological non-traumatic
pathologies. Finally, an additional result was that the
subgroup with the highest rate of ICP monitoring had the
lowest mortality suggesting a utility of monitoring and
treating high ICP.
Due to potential complication ICP related, even if
minor in good hands, non-invasive methods of ICP
measuring are appealing. Between others, the relationship
between optic nerve sheath diameter (ONSD) and ICP in
neurocritical care patients has been explored [4]. A sig-
nificant relationship between ONSD and ICP was
recorded. Changes in ICP were strongly correlated with
changes in ONSD. Enlarged ONSD was a suitable pre-
dictor of elevated ICP. Even if the studied cohort was
limited, non-invasive measurements were correlated with
invasive ICP. This method, once validated in a wider
number of patients, could be used as a screening test when
raised ICP is suspected.
Stocchetti [5] quantified, in a prospective study of
407 consecutive TBI patients, the occurrence of HICP
refractory to conventional medical therapy. In this TBI
subset more aggressive therapies, as profound hyper-
ventilation, barbiturates, decompressive craniectomy, are
currently used. HICP is frequent; 153 patients had at
least 1 day of ICP[20 mmHg. Early surgery was nec-
essary for 221 cases, and standard medical therapy
[sedation, mannitol, cerebrospinal fluid (CSF) with-
drawal, PaCO2 30–35 mmHg] was used in 135 patients.
Reinforced treatment (PaCO2 25–29 mmHg, induced
arterial hypertension, muscle relaxants) was used in 179
cases (44%), and second-tier therapies in 80 (20%).
Surgical decompression and/or barbiturates were used in
28 of 407 cases (7%). Six-month outcome was favorable
(good recovery or moderate disability) in 195 cases
(53%). HICP was associated with worse outcome. Out-
come for cases who had received second-tier therapies
was significantly worse (43% favorable at 6 months,
P = 0.03). Therefore, HICP is frequent and is associated
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with worse outcome. The indications for surgical
decompression and/or barbiturates seem restricted to less
than 10% of severe TBI.
The use of hyperventilation and the adherence to
international guidelines after TBI have been studied [6]
analyzing data coming from 22 European centers, partici-
pating in the BrainIT initiative (http://www.brainit.org).
One hundred and fifty-one patients and 7,703 ABGs, rep-
resenting 2,269 ventilation episodes (VE), were included in
the analysis. Patients without elevated intracranial pressure
(ICP \20 mmHg) manifested a statistically significant
higher PaCO2 (36 ± 5.7 mmHg) in comparison to patients
with elevated ICP (C20 mmHg (34 ± 5.4 mmHg). Inten-
sified forced hyperventilation (PaCO2 B 25 mmHg) in the
absence of elevated ICP was found in only 49 VE (2%).
Early prophylactic hyperventilation was used in 1,224 VE
(54%). During forced hyperventilation simultaneous
monitoring of cerebral oxygenation was used in only 9%.
Overall adherence to current guidelines seems common,
but early prophylactic hyperventilation and the use of
additional cerebral oxygenation monitoring during forced
hyperventilation are not followed exposing the patient to
potential iatrogenic complications.
After the acute phase, hormonal disturbances have
been described both in TBI and in subarachnoid hemor-
rhage patients. Maiya [7] retrospectively studied acute
anatomical changes in the pituitary gland in 41 TBI
patients undergoing magnetic resonance imaging (MRI)
during the acute phase. MRI scans from 43 normal
healthy volunteers were used as controls. The pituitary
glands were significantly enlarged in the TBI group.
Twelve of the 41 cases (30%) demonstrated focal chan-
ges. In approximately 30% of patients acute TBI was
associated with pituitary gland enlargement with specific
lesions. MRI of the pituitary may provide useful infor-
mation about the mechanisms involved in post-traumatic
hypopituitarism.
The Neuro-Intensive Care and Emergency Medicine
(NICEM) Section of the European Society of Intensive
Care Medicine (ESICM) developed a document on
neuromonitoring in neuro-intensive care [8]. The ques-
tions discussed and addressed in this manuscript were:
(1) Who should have ICP monitoring and for how
long? (2) What ICP technologies are available and what
are their relative advantages/disadvantages? (3) Should
CPP monitoring and autoregulation testing be used? (4)
When should brain tissue oxygen tension [PbrO(2)] be
monitored? (5) Should structurally normal or abnormal
tissue be monitored with PbrO(2)? (6) Should
microdialysis be considered in complex cases? This
articulated paper provide useful information to clini-
cians working in NICU and also to those developing
specialist NICU services within their hospital practice.
Subarachnoid hemorrhage
The paper by Schlenk [9] in patients with subarachnoid
hemorrhage suggests, as indicated by Strong [10] in the
accompanying editorial, that great caution is needed in
choice of a target range for plasma glucose if tight
glycemic control with insulin is undertaken. The Authors
in a prospective, nonrandomized, single-center study,
explored whether hyperglycemia exerts deleterious
effects via cerebral energy metabolism and the effects of
cerebral high/low glucose in patients with aneurysmal
subarachnoid hemorrhage. In all patients a microdialysis
catheter was inserted. Cerebral low-glucose episodes and
high-glucose episodes occurred independently of blood
glucose levels. During high-glucose episodes cerebral
microdialysate levels were normal, while cerebral low
glucose, occurring more frequently in symptomatic
patients, was associated with severe cellular distress, i.e.,
increase in lactate/pyruvate ratio, glutamate, glycerol and
with unfavorable outcome. Cerebral low glucose was
associated with severe metabolic distress and may present
a target for therapy to improve clinical outcome. Tight
glycemic control could be deleterious in this neurological
population.
Electrical activity in ICU/epilepsy
Legriel [11] studied 140 ICU patients with status epi-
lepticus (SE). Median seizure time was 60 min and 58
patients had seizures longer than 30 min. The most
common causes of SE were cerebral insult in 53% and
anticonvulsant drug withdrawal in 20% of patients. No
cause was identified in 35% of patients. Median time from
SE to treatment was 5. The SE was refractory in 25%
patients. Hospital mortality was 21%. By multivariate
analysis, independent predictors of 30-day mortality were
age, GCS at scene, continuous SE, symptomatic SE and
refractory SE. Further studies are needed to evaluate the
possible impact of early maximal anticonvulsant treat-
ment on outcomes.
An increasing interest is rising re-evaluating the utility
of monitoring cerebral electrical activity. This is done,
usually, with continuous EEG system even if other, sim-
pler, approaches are explored. Walsh [12] prospectively
assessed whether the Entropy Module, a device to mea-
sure hypnosis in anesthesia, is a valid measure of sedation
state in critically ill patients. Four hundred and seventy-
five trained observer assessments were made and com-
pared with concurrent entropy numbers. Entropy of the
frontal EEG does not discriminate sedation state
adequately for clinical use in ICU patients.
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Delirium and other neurological problems
Morandi [13] and coworkers undertook a multinational
effort to identify conflicts in terminology and phenome-
nology of delirium to facilitate communication across
medical disciplines and languages. The evaluation of the
terminology used for acute brain dysfunction was deter-
mined conducting communications with 24 authors from
academic communities throughout countries/regions that
speak the 13 variants of the Romanic languages included
into this manuscript. Interestingly only 54% use the term
delirium to indicate the disorder as defined by the DSM-
IV as an acute change in mental status, inattention, dis-
organized thinking and altered level of consciousness.
Attempts towards standardization in terminology, or at
least awareness of differences across languages and
specialties, will help cross-talk among clinicians and
researchers.
Cheung [14] surveyed the same topic in Canadian
ICUs with a response rate of 58.3%. When an etiological
cognitive dysfunction diagnosis was obvious, 83–85%
responded with the medical diagnosis to explain the
cognitive abnormalities; only 43–55% used the term
‘‘delirium’’. In contrast, where an underlying medical
problem was lacking, 74% of respondents diagnosed
‘‘delirium’’. Non-pharmacological and pharmacological
management varied considerably. Commonly selected
pharmacological agents were antipsychotics and benzo-
diazepines, followed by narcotics, non-narcotic
analgesics, and other sedatives. Canadian intensivists
diagnose delirium based upon the presence or absence of
an obvious medical etiology.
Looking for delirium scoring methods, Plaschke [15]
assessed the agreement between the delirium ratings of
two independent delirium assessment methods: the Con-
fusion Assessment method for the ICU and the Intensive
Care Delirium Screening Checklist (ICDSC). After
excluding permanently unconscious patients with B4 on
the Richmond Agitation Sedations scale (RASS), delirium
was identified in 71 of the 174 patients (41%). The
patients who were included were tested in 374 paired but
researcher-independent ratings of delirium by both scor-
ing methods. The kappa coefficient determined over
7 days of ICU stay was 0.80, indicating good agreement.
Soja [16] implemented delirium monitoring, test reli-
ability, and monitor compliance of performing the
Confusion Assessment Method for the Intensive Care
Unit (CAM-ICU) in trauma patients. Following a web-
based teaching module, bedside nurses evaluated patients
daily for depth of sedation with the RASS and for the
presence of delirium with the CAM-ICU. On randomly
assigned days, evaluations by nursing staff were followed
by evaluations by an expert evaluator to assess compli-
ance and reliability of the CAM-ICU in trauma patients.
Overall agreement (kappa) between nurses and expert
evaluator was 0.77. The survey revealed that nurses were
confident in performing the CAM-ICU, realized the
importance of delirium, and were satisfied with the
training that they received. Defining the etiology of
hyponatremia in acute neurological patients is a sometime
an intriguing challenge. Brimioulle [17] assessed whether
hyponatremia is associated with the syndrome of inap-
propriate antidiuretic hormone secretion (SIADH) or with
cerebral salt-wasting syndrome (CSWS). Measurement of
blood, plasma, and red blood cell volumes to discriminate
SIADH and CSWS. Renal, adrenal and thyroid functions
were normal in all patients. Average blood, plasma, and
red blood cell volumes were 54, 37 and 17 ml/kg in
control patients and 54, 37 and 18 ml/kg in hyponatremic
patients, respectively. The adequate blood volumes in
hyponatremic patients confirmed the diagnosis of SIADH
and did not support the concept of CSWS.
Hausfater [18] studied the effect of non-exertional
heatstroke on serum procalcitonin (PCT) levels in 53
patients with defined heatstroke during the August 2003
heat wave in France were analyzed; 30-day mortality was
recorded. Among the 53 patients included, 14 (26%) were
admitted to an intensive care unit (ICU). At 30 days, 24
patients (45%) had died. Median PCT value was 0.58 lg/l
and 31 (58%) patients had PCT above 0.2 lg/l (PCT?).
Temperature above or equal to 40C was the only variable
significantly associated with fatal outcome. Median PCT
values were similar between survivors and non-survivors
(P = 0.22). High serum PCT levels was observed in
heatstroke without concomitant bacterial infection. The
PCT was not a valid mortality predictor in heatstroke, but
could be an indicator of the severity of illness.
Endocrinology and renal failure
The use of a single dose of etomidate to facilitate
laryngeal intubation is still widespread in spite of the
demonstration of the potential of the drug to inhibit the
last step in cortisol synthesis in the adrenal cortex. The
recent CORTICUS study also shows the in vivo capability
of the drug to suppress ACTH-cortisol responses, at least
in septic patients. The clinical consequences, however,
remain unclear, in spite of awareness of the problem for
decades. The paper by Vinclair et al. [19] somewhat adds
to the evidence in describing the in vivo effects of
etomidate in non-septic patients in the course of time, in
terms of ratios of circulating 11b-deoxycortiol to cortisol,
reflecting in vivo activity of the last enzymatic step in
cortisol synthesis potentially inhibited by etomidate. The
results suggest, in the absence of a control group, that the
ratio increases after etomidate administration and is
associated with a diminished rise in circulating cortisol
upon ACTH. The etomidate effect has waned in 91% of
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patients after 48 h. Again, the clinical consequences
remain unclear.
Adrenal insufficiency has been recently observed in
critically ill patients with liver cirrhosis and severe sepsis.
du Cheyron et al. [20] thus postulated that hyperreninemic
hypoaldosteronism may be common and may have an
impact on outcome in patients with acute on chronic liver
failure. The authors thus investigated the relation between
the adrenal production of gluco- and mineralo-corticoids,
inflammatory status and outcome in critically ill patients
with liver cirrhosis. They included 50 consecutive
patients with liver cirrhosis and applied a corticotropin
stimulation test within 12 h following ICU admission.
Hyperreninemic hypoaldosteronism syndrome was
defined as basal renin over aldosterone ratio (RRA) higher
than 2. They found impaired adrenal function in 41 (82%)
patients. 26 patients (52%) presented with an RRA [2.
Patients with RRA [2 exhibited greater disease severity
and organ dysfunction scores at baseline, but risk-adjusted
mortality rates were not different between the two groups.
Renin and IL-6 plasma concentrations were positively
correlated. A Cox regression analysis revealed hyperren-
inemic hypoaldosteronism syndrome, IL-6 higher than
400 pg/ml and severe renal failure to be independent
predictors of 30-day mortality. The authors concluded
that adrenal dysfunction was common in critically ill
cirrhotic patients. Hyperreninemic hypoaldosteronism
syndrome was related to a greater pro-inflammatory status
and degree of acute organ failure, and was independently
associated with a worse prognosis.
In attempts to prevent harmful acute kidney injury
(AKI) and acute renal failure (ARF) in the critically ill,
control of intraabdominal hypertension may contribute.
To this end, accurate measurements of intraabdominal
pressure are warranted. Malbrain and colleagues [21]
compared 315 (15 observers) manual Foley catheter, and
automated Spiegelberg catheter and CiMON-balloon
catheter measurements with the applied hydrostatic
pressure in a 3-l container. The measurements (between
0–30 cm H2O) were very close to each other. It is
therefore suggested that manual are as good as automated
measurements (and vice versa).
Other preventive measures may include drug treat-
ments and in this context Heemskerk et al. [22] report on
the interesting potential of inhibiting NO-induced soluble
guanylate cyclase by methylene blue (MB) administra-
tion. In a small (n=9, uncontrolled) series of (refractory)
septic shock patients, they suggested on the basis of a
decrease in NO metabolites and excretion of renal tubular
injury markers in the urine that MB (4 mg/kg over 4 h)
was able to decrease renal tubular damage and increase
renal function parameters. However, the outcome benefits
of such treatment warrant further study. The results
obtained may thus increase our mechanistic rather than
therapeutic insight.
When AKI/ARF has nonetheless developed, renal
replacement therapy must be initiated, the type, timing
and dosing of which continues to be subject of debate. In
a randomized study on septic patients (n=10/9) with need
for renal replacement, high volume (65 ml/kg per h) was
compared with low volume (35 ml/kg per h) hemofiltra-
tion [23]. The former treatment resulted in less
norepinephrine requirements to maintain mean arterial
blood pressure and urine output tended to increase. There
was no effect on renal recovery/survival in this small, but
unique (randomized!) study, while the effect on hemo-
dynamics confirms observational data.
Extracorporeal therapy with polymyxin-B to scavenge
endotoxin in severely septic patients has been tried
before. In the study by Cantaluppi et al. [24] however, the
technique was used to evaluate its effect on circulating
proapoptotic factors in gram-negative sepsis (n=8 PMX-
B, n=8 standard care) that could play a role, among
others, in the development of organ damage such as AKI/
ARF. There were some indications that this therapy
indeed worked in this preliminary mechanistic study.
Circulating proapoptotic factors on cultured renal cells
diminished, as well as SOFA/RIFLE scores, proteinuria
and tubular enzymes. The data suggest a role of apoptosis
in the development of sepsis-related AKI/ARF.
When clinicians have decided on the basis of likeli-
hood of resuming endogenous renal function, to
discontinue renal replacement therapy, some patients later
again need such treatment. This issue has been addressed
retrospectively by Wu et al. [25] from Taiwan, who, not
unexpectedly, found that, among others, oliguria, high age
and SOFA, and a long period of prior need for renal
replacement predicted its recurrent need (in 30%, within
30 days). Indeed, some patients may have only partial
recovery of renal function or remain on renal replacement
therapy even months after the initial insult. Moreover,
AKI/ARF is a risk factor for chronic renal failure over
decades. The paper thus again nicely illustrates that AKI/
ARF with need for renal replacement therapy is not a
benign disorder and the future challenge, of course, is to
find ways to promote full recovery and limit (recurrent)
need for renal replacement therapy.
Two physiological reviews and notes have dealt with
renal failure, as part of a cardio-renal syndrome and as a
basis for renal replacement therapy [26, 27]. The authors
extend the link between heart and kidney beyond con-
gestive heart failure and also indicate a more aggressive
approach in the use of different renal therapies.
Hemofilter circuits used for extracorporal renal
replacement therapy have an expected lifespan of 48–72 h.
However, they often clot prematurely which impairs azo-
temic control and has also effects on costs and nursing
workload. Antithrombin (AT) deficiency has been associ-
ated with hemofilter thrombosis (HT) in patients with
sepsis. Lanquetot et al. [28] investigated whether there was
34
an association between AT level activity and HT occur-
rence during early continuous hemofiltration. They
included 48 consecutive patients following cardiopulmo-
nary bypass. Subjects were grouped according to the
appearance of one or more episodes of hemofilter throm-
bosis. Morbidity and mortality did not differ significantly
between the two groups. The authors found initial AT
activity to be low in both groups. On the following days AT
activity was lower in the HT group but was not found to be
a predictor of HT in multivariate analysis. The authors
concluded that the potential interest of monitoring AT
levels to adapt anticoagulant strategy needs to be analyzed
in larger series of patients.
Metabolism and nutrition
During 2008 there has been a number of studies over tight
glucose control. Honiden et al. [29] reported in a pro-
spective observational study that early tight glucose
control, within 48 h from ICU admission, was associated
with a better outcome in terms of mortality, ventilator free
days, and length of stay. Also after the use of stepwise
regression analysis, the differences between the two
groups remained associated with the timing of the tight
glucose control. The result calls for a prospective ran-
domized trial to address the timing of tight glucose
control. Two studies report of the advantages of a com-
puterized algorithm to facilitate and to increase success
rate of tight glucose control. Pachler et al. [30] evaluated
their algorithm in a small randomized study. They found a
mean blood glucose value within the target range and a
lower hyperglycemic index in the group using a com-
puterized algorithm, but also a shorter sampling interval.
Safety was evaluated by hypoglycemia, which was
inconclusive, with overall only one hypoglycemic event
in the 25 ? 25 patients. In a questionnaire, nurses were in
favor of the computerized algorithm. Vogelzang et al.
[31] report from a large observational study that the
hypoglycemia rate was low (0.85%) and that target level
was reached faster and with fewer samples when the
computerized algorithm was used. Lapichino et al. [32]
investigated if tight glucose control affected NO-metab-
olism as reflected by the circulating levels of asymmetric-
dimethylarginine. In a prospective study of 72 patients in
septic shock they found no difference attributable to tight
glucose control in clinical outcome parameters or in
asymmetric-dimethylarginine. Mean blood glucose were
110 versus 163 mg/dl, respectively, in the two groups.
Ornithine transcarbamylase deficiency is a rare disor-
der usually diagnosed in childhood, which may also have
an adult onset and which gives encephalopathy and
obscure unconsciousness. Panlaqui et al. [33] report of a
case and point out the possible treatment with hemodia-
filtration, protein elimination, and ammonia scavenging
medications. The possibility of recovery with correct
diagnosis and treatment makes awareness of such a rare
condition important.
Nutrition
Nguyen et al. [34] used manometry to study gastric
motility. In a small case-control study they showed that
critically ill patients have an impaired motility both in the
antrum and pyloric region. Furthermore, the synchroni-
zation between the two regions was also impaired in the
critically ill patients. Using gastric scintigraphic data
Nguyen et al. [35] also report from a small observational
study that the mode of sedation may influence gastric
emptying. Patients kept on midazolam and morphine had
a significantly slower gastric emptying as compared to
patients kept om propofol. The result clearly calls for a
larger prospective randomized study. The cumulated
energy deficit in ICU patients primarily on enteral nutri-
tion, which has been reported in several studies, is mainly
related to underfeeding during the initial week of ICU
stay. Desachy et al. [36] report of a prospective ran-
domized study in 100 consecutive patients given enteral
nutrition introduced stepwise or all at once. Success rate
in terms of calories delivered was significantly better in
the groups given the full dose of enteral nutrition from
start. That group had a larger fraction of gastric residues
[300 ml, but the rate of adverse events necessitating
complementary parenteral nutrition was similar in the two
groups. Adverse effects related to the use of prokinetic
therapy was reported by Nguyen et al. [37] in an obser-
vational study of 180 consecutive patients receiving
erythromycin, metoclopramide or the combination of the
two. Patients given the combination had a higher rate of
diarrhea, but no single patient had a positive toxin test for
Clostridium difficile.
The role of immuno-modulating diets (IMDs) in criti-
cally ill patients is controversial. Marik and colleagues
[38] in the November issue published a meta-analysis to
determine the impact of IMDs on hospital mortality,
nosocomial infections and length of stay (LOS) in criti-
cally ill patients.
By using the MEDLINE, Embase, Cochrane Register
of Controlled Trials as data source, were selected ran-
domized control trials (RCTs) that compared the outcome
of critically ill patients receiving an IMD or a control diet.
Twenty-four studies (with a total of 3,013 patients) were
included in the meta-analysis; 12 studies included ICU
patients, 5 burn patients and 7 trauma patients. Four of the
studies used formulas supplemented with arginine, two
with arginine and glutamine, nine with arginine and fish
oil (FO), two with arginine, glutamine and FO, six with
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glutamine alone and three studies used a formula sup-
plemented with FO alone. Overall IMDs had no effect on
mortality or LOS, but reduced the number of infections.
Mortality, infections and LOS were significantly lower
only in the ICU patients receiving the FO IMD. The
authors concluded that an IMD supplemented with FO
improved the outcome of medical ICU patients (with
SIRS/sepsis/ARDS). IMDs supplemented with arginine
with/without additional glutamine or FO do not appear to
offer an advantage over standard enteral formulas in ICU,
trauma and burn patients.
The ratio of omega-3 to omega-6 polyunsaturated fatty
acids in the diet is suggested to have implications on the
severity of the inflammatory response. Friesecke et al.
[39] randomized 177 consecutive patients on parenteral
nutrition, also stratified for SIRS or not, to receive a
standard fat emulsion or a fish-oil enriched emulsion rich
in omega-3 polyunsaturated fatty acids. Endpoints were
interleukin 6 and monocyte HLA-DR as well as a number
of morbidity/mortality parameters. No differences in any
of the parameters studied were seen, which illustrates the
difficulty to reproduce the promising results from animal
studies in a relevant clinical material.
Regulation of the activity of transcription factor NF-
kappaB is an important therapeutic effect of the major
omega-3 fatty acids in FO, eicosapentaenoic and doco-
sahexaenoic acid (EPA and DHA). Using the articles
obtained by a Pubmed research, Singer and colleagues
[40] reviewed three aspects of NF-kappaB/inflammatory
inhibition by fish oil: (1) the inhibition of the NF-kap-
paB pathway at different levels, (2) the production of
Resolvin D1 and Protectin D1 that are potent, endoge-
nous, DHA-derived lipid mediators that attenuate
neutrophil migration and tissue injury in peritonitis and
ischemia-reperfusion injury, (3) the modulation of vagal
tone with potential anti-inflammatory effects. The
authors concluded that whether the pleiotropic actions of
EPA/DHA contribute to FO’s therapeutic effect in sepsis
remained to be shown.
Sepsis and infections
In the January issue, in conjunction with Critical Care
Medicine was published the controversial guidelines for
management of severe sepsis and septic shock with the
intent of providing an update to the original Surviving
Sepsis Campaign clinical management guidelines, ‘‘Sur-
viving Sepsis Campaign guidelines for management of
severe sepsis and septic shock,’’ published in 2004 [41].
The authors used the GRADE system to guide assessment
of quality of evidence from high (A) to very low (D) and
to determine the strength of recommendations. Key rec-
ommendations, listed by category, include: early goal-
directed resuscitation of the septic patient during the first
6 h after recognition (1C); blood cultures prior to anti-
biotic therapy (1C); imaging studies performed promptly
to confirm potential source of infection (1C); adminis-
tration of broad-spectrum antibiotic therapy within 1 h of
diagnosis of septic shock (1B) and severe sepsis without
septic shock (1D); reassessment of antibiotic therapy with
microbiology and clinical data to narrow coverage, when
appropriate (1C); a usual 7–10 days of antibiotic therapy
guided by clinical response (1D); source control with
attention to the balance of risks and benefits of the chosen
method (1C); administration of either crystalloid or col-
loid fluid resuscitation (1B); fluid challenge to restore
mean circulating filling pressure (1C); reduction in rate of
fluid administration with rising filling pressures and no
improvement in tissue perfusion (1D); vasopressor pref-
erence for norepinephrine or dopamine to maintain an
initial target of mean arterial pressure [ or =65 mm Hg
(1C); dobutamine inotropic therapy when cardiac output
remains low despite fluid resuscitation and combined
inotropic/vasopressor therapy (1C); stress-dose steroid
therapy given only in septic shock after blood pressure is
identified to be poorly responsive to fluid and vasopressor
therapy (2C); recombinant activated protein C in patients
with severe sepsis and clinical assessment of high risk for
death (2B except 2C for post-operative patients). In the
absence of tissue hypoperfusion, coronary artery disease,
or acute hemorrhage, target a hemoglobin of 7–9 g/dl
(1B); a low tidal volume (1B) and limitation of inspira-
tory plateau pressure strategy (1C) for acute lung injury
(ALI)/acute respiratory distress syndrome (ARDS);
application of at least a minimal amount of positive end-
expiratory pressure in acute lung injury (1C); head of bed
elevation in mechanically ventilated patients unless con-
traindicated (1B); avoiding routine use of pulmonary
artery catheters in ALI/ARDS (1A); to decrease days of
mechanical ventilation and ICU length of stay, a conser-
vative fluid strategy for patients with established ALI/
ARDS who are not in shock (1C); protocols for weaning
and sedation/analgesia (1B); using either intermittent
bolus sedation or continuous infusion sedation with daily
interruptions or lightening (1B); avoidance of neuro-
muscular blockers, if at all possible (1B); institution of
glycemic control (1B) targeting a blood glucose
\150 mg/dl after initial stabilization (2C); equivalency of
continuous veno-veno hemofiltration or intermittent
hemodialysis (2B); prophylaxis for deep vein thrombosis
(1A); use of stress ulcer prophylaxis to prevent upper GI
bleeding using H2 blockers (1A) or proton pump inhibi-
tors (1B); and consideration of limitation of support
where appropriate (1D). Recommendations specific to
pediatric severe sepsis include: greater use of physical
examination therapeutic end points (2C); dopamine as the
first drug of choice for hypotension (2C); steroids only in
children with suspected or proven adrenal insufficiency
36
(2C); a recommendation against the use of recombinant
activated protein C in children (1B). The authors con-
cluded that evidenced-based recommendations regarding
the acute management of sepsis and septic shock are the
first step toward improved outcomes for this important
group of critically ill patients.
The field of biomarkers for systemic inflammatory
response syndrome (SIRS) and sepsis is continuously
evolving. The role of osteopontin, a protein with cell
signaling functions in the interstitium upon inflammation,
has been studied as a sepsis marker, by Vaschetto
et al.[42] in 56 SIRS/sepsis patients (vs. 56 controls). The
investigators demonstrated that circulating osteopontin
could be used as a marker of IL-6 release and of sepsis
(vs. SIRS), even though the levels were elevated in SIRS
(vs. control) as well. Osteopontin appeared capable of
increasing IL-6 secretion by macrophages in vitro. It is
unclear how specific the findings were for microbial
infection, however. Dulhunty et al. [43] reported on a
multi-center study (n = 3,543 patients) done in Australia
and New Zealand to answer the question whether severe
non-infectious SIRS differs from severe sepsis in the ICU,
regarding epidemiological issues. Even though mortality
rates were similar, severe non-septic SIRS was more
common and more often associated with neurological
abnormalities and causes of death, than severe sepsis.
This study adds to the idea that infection per se is not a
major determinant of patient outcome, in contrast to the
response of the body to either non-infectious or infectious
threats.
Interactions of inflammatory mediators (or biomark-
ers) in sepsis remain immensely complex. de Kruif et al.
[44] demonstrated that some of these biomarkers are
dose-dependently inhibited by corticosteroid treatment,
and variations in the gene expression of interleukins 23
and 27 appeared to be different between septic ICU
patients, non-septic bacteremic patients and healthy con-
trols [45]. And patients undergoing elective cardiac
surgery, preoperative levels of apolipoprotein CI were
associated with increased perioperative levels of TNF-
alpha in patients experiencing endotoxemia [46].
Payen and colleagues [47] assessed blood leucocytes
gene profiling in the course of the septic shock recovery
period and tested the relation between encoding gene
expression and protein level in 17 septic shock patients.
Gene expression levels were studied on a dedicated
microarray of 340 genes involved in inflammatory pro-
cesses. The time-related gene expression study showed
significant changes in ten genes. Among them, S100A8
and S100A12 had a reduced expression over time com-
pared with D0, whereas CD74’s expression increased. By
RT-qPCR, the S100A8 plasma levels decrease in parallel
with the gene expression decrease. The CD74 gene
expression evolution significantly correlated with HLA-
DR monocyte expression.
Moreno and coworkers [48] wished to evaluate the
value of the PIRO concept in septic patients. PIRO stands
for predisposition, infection, response and outcome. The
predictive value for outcome of premorbid factors, toge-
ther with infectious features in the ICU and the
subsequent changes in sequential organ failure assessment
(SOFA) were evaluated. The SAPS 3 database was used
for this purpose, on 2,628 patients with signs of infection
in the ICU [48 h. Sepsis, severe sepsis and septic shock
were defined according to standard criteria. Hospital
mortality was 41%. Predictive factors were scored as the
SAPS 3 PIRO score which appeared to have excellent
(even somewhat better than the SAPS 3 model) predictive
value for mortality. The conclusion of the authors is that
PIRO components independently contribute to outcome
prediction. Thereby, the study is one of the first to argue
in favor of the clinical validity as well as the practicability
or usefulness of the PIRO concept.
Early identification of septic patients at high risk of
death may provide an opportunity to change the treat-
ment strategy to improve the outcome. Because plasma
midregional pro-atrial natriuretic peptide (MR-proANP)
concentrations have recently emerged as a valuable tool
for individual risk assessment in such a setting, Seligman
et al. investigated the prognostic role of this marker in 71
consecutive patients who developed VAP [49]. The study
demonstrated that MR-proANP levels were significantly
higher in VAP patients dying within 28 days when
compared to survivors. In multivariate logistic regression
models of predictors of death including age, sex,
APACHE II, and blood creatinine, MR-proANP levels
on the day of diagnosis of VAP and on day 4 turned out
to be the only parameters that remained as independent
predictors.
Lipoproteins, and in particular high-density lipopro-
teins (HDL), have been demonstrated to play an important
role in modulating inflammation and the response to
infection. Because apolipoprotein CI (apoCI) protects
against the development of murine bacterial sepsis and is
virtually completely depleted in human sepsis, its time-
course in patients with severe sepsis may predict survival.
This hypothesis was confirmed in a small pilot study
performed by Berbee et al. [50]. Upon hospitalization,
apoCI levels were approximately 5 times lower than
normal values in 16 septic patients. Remarkably, apoCI
levels remained low in non-survivors, whereas apoCI
levels gradually increased to normal levels in survivors.
During the host response to infection and the devel-
opment of sepsis and shock, vasopressor-insensitive
hypotension (shock) may supervene for which the clini-
cian may consider adjunctive therapy with hydrocortisone.
Kaufmann et al. [51] again demonstrated in 30 patients
with septic shock that hydrocortisone treatment decreases
vasopressor requirements and circulating IL-6. Moreover,
this therapy preserved opsonization (zymosan)-dependent
37
neutrophil functions, while suppressing spontaneous
hydrogen peroxide release (flow cytometry). The (small)
study was placebo-controlled. These data may help our
understanding of the mechanism of action of steroid
therapy in septic shock and suggest that hydrocortisone
has no major immunosuppressive effects on neutrophils
limiting host defences.
Severe sepsis and septic shock are serious complica-
tions of hematological malignancies. Vandijck and
colleagues [52] compared characteristics and outcomes in
ICU patients with hematological malignancies and severe
sepsis/septic shock who had or had not received recent
intravenous chemotherapy. Among the 186 patients, there
were 77 patients with severe sepsis and 109 with septic
shock; 91 (49%) had received recent intravenous che-
motherapy. In-hospital, and 6-month mortality rates were
45.1 versus 58.9%, and 50.5 versus 63.2% in patients with
and without recent chemotherapy, respectively. By mul-
tivariate analysis, previous chemotherapy was protective.
After adjustment with a propensity score for recent che-
motherapy, chemotherapy was not associated with
outcome.
Activated protein C for severe sepsis patients is a
controversial therapy. In the study of Kalil and Sun [53],
the authors aimed to respond to two questions. The first
was, what is the current probability that activated protein
C is not better than the control? and, if the current
probability is not small, then the second question was,
how many patients will be needed for the activated pro-
tein C confirmatory trial? To give an adequate response to
these questions, the authors used a Bayesian statistical
approach. The P value commonly used in frequentist
statistical methods only tell us how likely we will observe
the reported data when the null hypothesis is true, but
does not tell us the actual probability of treatment effect.
Bayesian methodology, however, can provide this actual
(or current) probability. To do this, all available data is
selected for the prior probability. The prior distributions
were defined as severe skeptic, moderate skeptic, mild
skeptic and enthusiastic. The authors found that, except
for the enthusiastic analysis, the current probabilities that
activated protein C is not better than the control are not
small (range, 0.14-0.48). The number of patients needed
for a confirmatory trial ranged between 0 and 8,350. The
authors concluded that a confirmatory trial with about 600
patients with severe sepsis and high risk of death can
provide a convincing answer for moderate and mild
skeptic physicians regarding the efficacy of the drug.
In a special article published in the November issue
Finfer et al. [54] report on the ongoing new trial of acti-
vated protein C for persistent septic shock. The authors,
members of the steering committee of the trial, fully
discuss the potential benefits and harm of this drug and
provide in-depth explanations about organizational issues
and the sponsor’s role, the design and the goals of this
ongoing study, the safety monitoring and the analysis and
report of the data. A full disclosure of the conflicts of
interest is provided in the ESM file accompanying this
article, together with the complete study protocol.
Because its particular characteristics, this article is
accompanied by editors’ comments [55], and two edito-
rials: one providing an European view on this issue [56],
the other providing a North-American view [57].
Infections and pneumonia
Intravascular-device related infections remain among the
most frequent infectious complications of intensive care
treatment. Yet, the absolute risk on infection per catheter
per day is low, hampering the analysis of intervention
studies aimed to reduce this incidence. In a large study by
Gowardman et al. [58], the incidence density of tip col-
onization (15.1/1,000 catheter days) was almost ten times
as high as that of catheter-related infection (1.8/1,000
catheter days). In another observational study, the inci-
dence density of arterial catheter colonization was 19.9
per 1000 catheter days, and the relative risk of coloniza-
tion increased in time [59], as did the risk for central
venous catheter-related infection in a Spanish multi-cen-
ter study [60].
Indeed, bacterial growth on the tip of catheters has
been used as a proxy for catheter-related infections. In a
prospective study, Souweine and coworkers [61] deter-
mined that in patients without a clinical suspicion of
catheter-related infection, the chance of bacterial growth
on the tip was 4.7% (8.0 per 1,000 catheter days) and that
administration of antibiotics at the time of removal was
associated with a lower risk of tip colonization. Therefore,
proportions of patients on antibiotics at the time of line
removal should be taken into account when using this
proxy as an endpoint.
All predictions are difficult, especially when they
involve the outcome of infections and sepsis. Yet, several
studies aimed to identify accurate prognostic factors. An
increment of C-reactive protein of 10 mg/l increased the
odds of death after ICU-discharge with 1.09 (95% CI
1.03–1.16) after adjustment for age, APACHE II score
predicted mortality and Delta SOFA with an area under
the receiver operating characteristic curve of 0.85 (95%
CI 0.73–0.96) [62]. In ICU patients, high loads of herpes
simplex type I virus in bronchoalveolar lavage fluid were
associated with mortality. Boer and coworkers [63]
developed a prognostic model for the presence of post-
traumatic stress syndrome after abdominal sepsis, that
included age, length of ICU stay and having traumatic
memories of the ICU or hospital stay [64].
The numbers of studies evaluating genetic associations
with outcome is now rapidly increasing. Angiotensin-
converting enzyme insertion/deletion polymorphism was
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not associated with outcome in sepsis and ARDS (Villar
et al. [65]).
Selective Decontamination of the Digestive Tract
(SDD) is a frequently used infection prevention measure
in some countries. In SDD, non-absorbable antibiotics are
applied topically and it has been assumed that detectable
systemic levels of these agents, such as tobramycin, will
not be reached. However, detectable serum levels of
tobramycin were measured in 63% of patients receiving
both SDD and CVVH. One patient had a toxic level of
3 mg/l [66]. In a randomized cross-over study, Lang-
gartner and coworkers [67] demonstrated that appropriate
bacterial concentrations of meropenem in patients on
continuous renal replacement therapy could be achieved
with continuous infusion, with similar areas under the
curve but longer times above the MIC as with intermittent
bolus injection.
Water sinks are considered as relevant sources for
many bacterial species, including Pseudomonas aerugin-
osa. In a non-outbreak setting, these bacteria were
isolated from 86% of samples taken from U-bends and in
5% of those from tap water. Yet, based upon genotyping,
only 1 of 14 patients was colonized by a P. aeruginosa
clone also isolated from water samples [68].
Candida infections remain a crucial issue in the ICU.
In a 1-year National perspective observational study
conducted in 24 adult French ICUs Bougnoux and
colleagues [69] determined the concomitant incidence,
molecular diversity, management and outcome. The study
enrolled 262 with nosocomial candidemia and/or candid-
uria. The mean incidences of candidemia and candiduria
were 6.7 and 27.4/1,000 admissions, respectively. Eight
percent of candiduric patients developed candidemia with
the same species. The mean interval between ICU
admission and candidemia was 19.0 ±2.9 days, and 17.2
±1.1 days for candiduria. C. albicans and C. glabrata
were isolated in 54.2 and 17% of blood and 66.5 and
21.6% of urine Candida-positive cultures, respectively.
Fluconazole was the most frequently prescribed agent.
Crude ICU mortality was 61.8% for candidemic and
31.3% for candiduric patients. Seventy-five percent of the
patients were infected with a unique C. albicans strain;
cross-transmission between seven patients was suggested
in one hospital. No difference in susceptibility and genetic
background were found between blood and urine strains of
Candida species.
It is difficult to judge the quality of care in different
ICUs. Objective and reproducible criteria are badly
needed, but hampered by the absence of a gold standard.
Najjar-Pellet and coworkers [70] proposed a scoring sys-
tem based upon 95 variables that might serve as a tool for
quality assessment in future studies. One quality variable,
not included in the previously mentioned scoring system,
is the recognition of rare diseases, such as, for instance
acute disseminated encephalomyelitis (ADEM). In a
retrospective multi-center study of 6 years Sonneville and
coworkers [71] describe the characteristics of 20 ADEM
patients needing ICU admission. ADEM is not a benign
disease, as 25% of the patients died and 35% had persistent
functional sequelae.
P Damas and colleagues [72] in an observational
single-center study assessed the temporal relationship
between ICU-acquired infection (IAI) and the preva-
lence and severity of organ dysfunction or failure (OD/
F). Almost 2,200 patients hospitalized for more than
2 days during a 2-year observation period were studied:
845 did not acquire IAI, 306 of whom had infection on
admission (IOA); 346 did acquire IAI, 125 of whom
had IOA. The SAPS II and SOFA score of the first
24 h were significantly higher in patients with than in
those without IAI. SOFApreinf of IAI patients was also
higher than the SOFAmax of patients without IAI both
in patients with (12.1 ± 4.6 vs. 8.9 ± 4.7) and those
without IOA (9.2 ± 4.0 vs. 6.7 ± 3.5). SOFApreinf
represented 85.7% of the value of SOFAmax in patients
with IAI. SOFApreinf increased significantly with the
occurrence of sepsis, severe sepsis, or septic shock
during ICU stay. The authors concluded that ICU-
acquired infections are significantly associated with
hospital mortality; but thir contribution to OD/F sems
minor.
Advances in treatment
Aminoglycosides are broad-spectrum antibiotics active
against most pathogens responsible for ventilator-associ-
ated pneumonia (VAP), even those with multidrug-
resistance patterns. However, the systemic use of this
antibiotic class is limited by its toxicity and poor pene-
tration into the lung. Aerosol administration offers the
theoretical advantage of achieving high antibiotic con-
centrations at the infection site and low systemic
absorption, thereby avoiding renal toxicity. However,
some uncertainties persist regarding the real usefulness of
such a mode of administration, since during mechanical
ventilation (MV), high amounts of the particles dispersed
by conventional nebulizers remain in the ventilatory cir-
cuits and the tracheobronchial tree before reaching the
distal lung. In a study carried out in subjects with healthy
lungs, Ehrmann et al. [73] showed that, using an opti-
mized nebulization technique with a vertical spacer
placed underneath a vibrating mesh nebulizer, doses of
60 mg/kg amikacin were associated with serum concen-
trations equal to or less than those obtained after
intravenous infusion of 15 mg/kg amikacin. Because
amikacin systemic pharmacokinetics reflect deposition of
the nebulized drug in the distal pulmonary parenchyma,
these data strongly support the hypothesis that optimized
nebulization of antimicrobial agents may permit to obtain
very high lung parenchyma concentrations during a
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sufficiently long period of time for achieving bactericidal
activity.
Despite advances in prophylactic perioperative anti-
biotic therapy, post-operative pneumonia is a feared
complication following major surgery and is associated
with an ICU mortality of 10–20%. One of the major
predisposing factors is insufficient target-site concentra-
tion of antibiotics used for prophylaxis. Because
ventilation/perfusion mismatch due to atelectasis may
also influence antibiotic distribution to lung tissue, hence
increasing the risk of post-operative pneumonia, Hutsc-
hala et al. compared the penetration of levofloxacin into
the lung of two groups of patients, using microdialysis
probes to sequentially determine in vivo lung tissue lev-
els. The first group consisted of five patients who
underwent coronary artery bypass grafting (CABG) with
cardiopulmonary bypass (CPB) (atelectasis model), and
the second one, of five patients operated with the off-
pump coronary artery bypass grafting (OPCAB)-tech-
nique [74]. In the OPCAB-group, the median of the
maximum concentration of levofloxacin in lung tissue
was significantly higher compared with the CPB-group,
establishing that atelectasis formations lead to critically
lower lung tissue concentrations of levofloxacin in non-
dependent parts of lung tissue. Such data emphasizes the
necessity of direct interstitial antibiotic measurement to
re-evaluate commonly accepted prophylactic and thera-
peutic antibiotic dosages in various clinical settings and
pulmonary diseases associated with the formation of
atelectasis.
To favorably impact the outcome of patients with
severe nosocomial sepsis, antibiotic therapy covering the
offending pathogen has to be initiated without delay,
which implies administration within 24 h of clinical
deterioration. In patients at risk for infection with multi-
drug resistant (MDR) pathogens, the clinician has to
resort to broad-spectrum antimicrobials, which are
themselves linked with the emergence of multi-drug
resistance. The potential value of systematic endotracheal
tracheal surveillance cultures as a tool to predict
involvement of MDR microorganisms in VAP was stud-
ied by two independent groups of investigators [75, 76].
In the first study, Depuydt et al. were able to document
that a 3-weekly tracheal aspirate protocol in intubated
patients had a sensitivity to predict MDR pathogens of
69% with a specificity of 96%. Appropriate antibiotic
coverage within 24 and 48 h following MDR VAP was 77
and 89%, respectively. A carbapenem-based empirical
scheme would have been equally appropriate (83 vs. 77%
at 24 h; 83 vs. 89% at 48 h), but a beta-lactam-fluoro-
quinolone empirical therapy would have been less (59 vs.
77% at 24 h; 59 vs. 89% at 48 h) as would have been
beta-lactam-aminoglycoside therapy (68 vs. 77% at 24 h;
68 vs. 89% at 48 h). Very similar results were obtained by
Papadomichelakis et al. in a retrospective cohort study of
patients who had developed VAP or bloodstream
infection (BSI) caused by a MDR pathogen, and in whom
tracheal aspirates were obtained twice weekly and rectal
swabs once weekly. Knowledge of previous colonization
improved the rate of adequate empiric antimicrobial
treatment (91 vs. 40% in VAP and 86 vs. 50% in BSI
cases, P \ 0.05), confirming that colonization surveil-
lance for resistant gram-negative microorganisms is
predictive of subsequent infection etiology and can
improve empiric antimicrobial treatment adequacy in a
critical care setting.
International guidelines recommend screening
patients for methicillin-resistant Staphylococcus aureus
(MRSA) on admission, although consensus on sites
required for optimum detection has not been reached. To
determine whether throat and rectal swabs identified a
significant number of additional MRSA-colonized
patients not captured by swabbing at keratinized skin
carriage sites (anterior nares, perineum and axillae),
Batra et al. [77] evaluated 1,470 consecutive ICU
patients. One hundred and five (7%) patients were
admitted with MRSA, of which only 63 (60%) were
detected by a pooled keratinized skin swab. A further 36
(34%) patients were detected only by throat or rectal
swabs. Indeed, throat and rectal swabs combined had a
higher sensitivity than pooled keratinised skin swabs (76
vs. 60% P = 0.03). Thus, a complete identification of
patients colonized by MRSA may need sampling of the
throat and rectum, and not only the anterior nares,
axillae, and peritoneum.
Bacterial colonization of the respiratory tract fre-
quently persists, even when a patient receives
antimicrobial treatment, and even though the colonizing
bacteria are, in vitro, susceptible to the antibiotics. To test
the hypothesis that antibiotics with presumed efficacy,
based on in vitro susceptibility testing, reduce the likeli-
hood of persistence of respiratory tract colonization,
compared to antibiotics presumed to be ineffective or
when no antibiotics were administered at all, Visscher
et al. [78] analyzed endotracheal aspirate cultures per-
formed during ICU stay in a large cohort of 715
mechanically ventilated ICU patients. Systemic antibiot-
ics were administered on 7,102 (61%) of patient days.
Antibiotic use was associated with non-persistence for all
pathogens, except Acinetobacter species and P. aerugin-
osa. Relative risks for non-persistence (as compared to
ineffective or no antibiotics) ranged from 3.1 (95% CI
1.4–6.6) for H. influenzae to 0.5 (0.3–1.0) for Acineto-
bacter species. Pathogen-specific characteristics, such as
the ability of biofilm formation of P. aeruginosa, or
patient-specific characteristics, such as the severity of
underlying disease or immune paralysis, could both be
involved, but further studies are needed to elucidate this
matter.
Unlike Mycobacterium tuberculosis, nontuberculous
mycobacteria (NTM) exist in the environment and can be
isolated from clinical specimens in the absence of true
40
infection. In patients with complicated and critical con-
ditions, such as those admitted to ICU, the clinical
significance of NTM in respiratory specimens and the
prognostic impact of NTM pulmonary infection are even
more difficult to understand than in stable patients.
Therefore, Shu et al. conducted a retrospective study
including all medical ICU patients with NTM being iso-
lated from respiratory specimens within a period of
8.5 years to evaluate the clinical significance of the
presence of NTM and compare the demographic charac-
teristics, clinical manifestations, and outcome in patients
with NTM pulmonary infection with those with NTM
colonization and control subjects whose respiratory
samples were culture-negative for mycobacteria [79].
Among the 5,378 patients admitted to medical ICUs,
NTM were isolated from 169 (5.8%) patients. Of them, 47
(28%) were considered NTM pulmonary infection.
Within 100 days after ICU admission, significantly more
patients with NTM infection died than those with NTM
colonization and control subjects (47 vs. 8 vs. 14%,
P \ 0.001). Therefore, keeping a high suspicion when
NTM is isolated and using careful consideration when
starting anti-NTM treatment should be emphasized.
Diagnosis
In the absence of a clinically available gold standard,
VAP is usually diagnosed according to a combination of
criteria, such as systemic signs of infection, abnormalities
on chest radiograph, and microbiological identification of
pathogens; however, each of these criterions combines
high sensitivity with low specificity. In an attempt to raise
diagnostic accuracy, Luyt et al. [80] assesses the predic-
tive capacity for the diagnosis of VAP of serum
procalcitonin levels before and on the day it is suspected.
Among the 73 suspected episodes VAP was confirmed by
quantitative bronchoalveolar lavage cultures in 32 and
refuted in 41. On day 1 a 0.5 ng/ml procalcitonin
threshold had 72% sensitivity but only 24% specificity for
diagnosing VAP. Between ‘‘before’’ and day 1, procalc-
itonin increased in 41 and 15% of patients with and
without VAP, respectively. Thus, crude values and pro-
calcitonin rise had poor diagnostic value for VAP in this
particular setting and should not be used to initiate anti-
biotics when VAP is clinically suspected.
Mixed results were also observed by El Solh et al. [81]
when they examined the potential role of serum and
alveolar soluble triggering receptor expressed on myeloid
cells (sTREM-1) as a biological marker of pulmonary
aspiration syndromes. While circulating levels of
sTREM-1 were comparable between those with aspiration
syndromes and controls, the alveolar levels of sTREM-1
were higher in patients with culture-positive pulmonary
aspiration compared with those culture-negative pul-
monary aspiration (P \ 0.001). A cut-off value of
250 pg/ml for alveolar sTREM-1 achieved a sensitivity of
66% and a specificity of 92% with an area under the curve
of 0.87.
Because cells and secretions recovered by bronchoal-
veolar lavage (BAL) can be microscopically examined
immediately after the procedure to detect the presence or
absence of intracellular or extracellular bacteria in the
lower respiratory tract, this technique is particularly well
suited to provide rapid identification of patients with
pneumonia. However, it is commonly assumed that prior
antimicrobial therapy can dramatically decrease its sen-
sitivity. In order to re-assess the influence of antibiotics
on the value of various BAL cytological parameters in
diagnosing VAP, Linssen et al. [82] studied 335 episodes
of clinically suspected VAP in 282 patients. There was no
difference in areas under the curve (AUCs) of receiver
operating characteristic curves between patients with and
without antibiotic therapy for any parameter studied. The
most prominent AUCs were: total cell count, 0.65; per-
centage polymorphonuclear neutrophils, 0.71; and
percentage infected cells, 0.90. Based on these data, it
appears that the percentage of infected cells in BALF can
be reliably used for diagnosing VAP in patients receiving
antibiotic therapy, provided that the introduction of the
new antibiotics was recent (less than 72 h).
Prevention
VAP remains a major problem in intensive care units
and effective preventive measures are eagerly searched
for. The presence of an endotracheal tube (ETT) not
only compromises the natural barrier between the oro-
pharynx and trachea, but also provides a protected
environment for pathogens since a biofilm develops on
its inner and outer surfaces. In an attempt to prevent
bacterial colonization of the lower respiratory tract in
patients requiring mechanical ventilation, Berra et al.
[83] developed a polyurethane ETT coated with silver
sulfadiazine. In a second study, the same group of
investigators randomized 46 adult patients to be intu-
bated with a standard non-coated ETT, or with a silver
sulfadiazine-coated ETT [84]. Coating with silver sul-
fadiazine prevented bacterial colonization of the ETT
and was associated with a thinner mucus layer. Although
preliminary, these data support the hypothesis that an
endotracheal tube coated externally and internally with a
potent antiseptic product such as silver could exert a
sustained antimicrobial effect within the proximal air-
ways and block biofilm formation at its surface.
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